Paul A. Mahon Sells 6,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHRGet Rating) EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $189.18, for a total transaction of $1,135,080.00. Following the transaction, the executive vice president now owns 36,397 shares of the company’s stock, valued at approximately $6,885,584.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of UTHR traded down $2.59 during midday trading on Friday, hitting $187.63. The stock had a trading volume of 377,924 shares, compared to its average volume of 448,792. United Therapeutics Co. has a 1 year low of $158.38 and a 1 year high of $218.38. The firm has a market cap of $8.47 billion, a PE ratio of 18.97, a price-to-earnings-growth ratio of 7.39 and a beta of 0.67. The company has a debt-to-equity ratio of 0.20, a current ratio of 7.61 and a quick ratio of 7.30. The stock’s 50 day moving average is $182.81 and its 200 day moving average is $193.23.

United Therapeutics (NASDAQ:UTHRGet Rating) last posted its quarterly earnings results on Thursday, February 24th. The biotechnology company reported $2.35 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.77 by ($1.42). The company had revenue of $415.20 million during the quarter, compared to analysts’ expectations of $427.59 million. United Therapeutics had a return on equity of 12.80% and a net margin of 28.23%. The company’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.19 EPS. As a group, equities research analysts expect that United Therapeutics Co. will post 14.04 earnings per share for the current fiscal year.

Several research firms have commented on UTHR. BTIG Research began coverage on shares of United Therapeutics in a research report on Friday, February 11th. They set a “neutral” rating for the company. LADENBURG THALM/SH SH lowered their price objective on shares of United Therapeutics from $231.00 to $203.00 and set a “buy” rating for the company in a research report on Friday, February 25th. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $230.00 to $223.00 and set an “overweight” rating for the company in a research report on Tuesday. HC Wainwright reiterated a “buy” rating on shares of United Therapeutics in a research report on Friday, February 25th. Finally, Zacks Investment Research lowered shares of United Therapeutics from a “buy” rating to a “hold” rating and set a $175.00 price objective for the company. in a research report on Tuesday, March 1st. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $215.00.

A number of hedge funds have recently bought and sold shares of the stock. State Street Corp increased its stake in United Therapeutics by 3.7% in the 4th quarter. State Street Corp now owns 1,517,265 shares of the biotechnology company’s stock worth $327,851,000 after buying an additional 54,462 shares during the period. Bank of New York Mellon Corp increased its stake in United Therapeutics by 17.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 844,958 shares of the biotechnology company’s stock worth $155,962,000 after buying an additional 123,295 shares during the period. Deutsche Bank AG increased its stake in United Therapeutics by 542.3% in the 3rd quarter. Deutsche Bank AG now owns 843,437 shares of the biotechnology company’s stock worth $155,681,000 after buying an additional 712,117 shares during the period. Geode Capital Management LLC increased its stake in United Therapeutics by 9.0% in the 4th quarter. Geode Capital Management LLC now owns 760,948 shares of the biotechnology company’s stock worth $164,425,000 after buying an additional 62,882 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its stake in United Therapeutics by 4.2% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 731,390 shares of the biotechnology company’s stock worth $158,039,000 after buying an additional 29,292 shares during the period. 96.46% of the stock is currently owned by institutional investors.

About United Therapeutics (Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.